Study on the Safety, Tolerability, and Preliminary Efficacy of 161Tb-NYM032 in Patients with Metastatic Castration-Resistant Prostate Cancer

Inclusion Criteria

• •1. The participant voluntarily signs the informed consent form and is able to complete the trial according to the protocol requirements.
• •2. Male, aged 18 years or older.
• •3. Diagnosed with metastatic castration-resistant prostate cancer (mCRPC) as per PCWG3 criteria.
• •4. Positive results on 68Ga-NYM032 positron emission tomography (PET)/computed tomography (CT) scan.
• •5. Must have received at least one NAAD treatment (e.g., enzalutamide and/or abiraterone) or at least one taxane-based treatment regimen, or be intolerant to or refuse taxane therapy for metastatic castration-resistant prostate cancer.
• •6. ECOG performance status of 0-2.
• •7. Expected survival of ≥6 months.
• •8. Laboratory parameters must meet the following:
• •1. ALT and AST must not exceed 3 times the upper limit of normal (ULN); BUN and Cr must not exceed 1.5 times the ULN.
• •2. Blood counts: WBC ≥3.5×10\^9/L, PLT ≥100×10\^9/L, Hb ≥90 g/L.